

The Asymmetric Cu(II)-Indolinylmethanol Complex Catalyzed Diels-Alder Reaction of 2-Vinylindoles with β,γ - Unsaturated α -Ketoesters: An Efficient Route to Functionalized Tetrahydrocarbazoles

Banlai Ouyang,^a Tingting Yu,^a Renshi Luo,^a and Gui Lu^{a,b,*}

^a Institute of Medicinal Chemistry, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, P. R. China

^b Institute of Human Virology, Sun Yat-sen University, Guangzhou 510080, P. R. China.

Fax: (+86)-20-39943048

E-mail: lugui@mail.sysu.edu.cn

Supporting Information

1. General information
2. Preparation of ligands
3. Synthesis of β,γ -unsaturated α -ketoesters 1a-f, 1h, 1j-k, 1m-n and 1p
4. Synthesis of β,γ -unsaturated α -ketoesters 1g, 1i, 1l and 1o
5. Preparation of 2-vinylindoles 2
6. General procedure for the asymmetric Diels–Alder reaction
7. References
8. HPLC spectra
9. ^1H and ^{13}C NMR spectra

1. General information


All reactions were carried out under an atmosphere of nitrogen in flame dried glassware with magnetic stirring. The solvents were distilled from standard drying agents. Unless otherwise stated, commercial reagents purchased from Alfa Aesar, Acros and Aldrich chemical companies were used without further purification. Purification of reaction products was carried out by flash chromatography using Qing Dao Sea Chemical Reagent silica gel (200-300 mesh).

¹H NMR spectra were recorded on a Bruker Advance III spectrometer (400 MHz). Chemical shifts were reported as parts per million (ppm) in the δ scale downfield from TMS. Peaks were labeled as singlet (s), doublet (d), triplet (t), quartet (q) and multiplet (m). ¹³C NMR spectra were recorded on Bruker spectrometer with complete proton decoupling, and chemical shifts were reported in ppm from TMS with the solvent as the internal reference (CDCl₃, δ = 77.0 ppm). HPLC analyses were conducted on an Agilent 1200 instrument using Daicel columns (0.46 cm diameter × 25 cm length). Optical rotations were recorded on a Perkin Elmer polarimeter (Model 341). MS spectra were recorded on an ESI-ion trap Mass spectrometer (Shimadzu LCMS-IT-TOF). Analytical TLC was performed using EM separations percolated silica gel 0.2 mm layer UV 254 fluorescent sheets.

2. Preparation of ligands


The ligands were prepared following the literature methods.

(S)-Indolin-2-ylidiphenylmethanol (L1)¹



[*a*]_D²⁰ = -105.0 (c = 1.0, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ: 7.62 (d, *J* = 7.4 Hz, 2H), 7.53 (d, *J* = 7.4 Hz, 2H), 7.40-7.15 (m, 6H), 6.99 (t, *J* = 7.7 Hz, 2H), 6.71 (t, *J* = 7.4 Hz, 1H), 6.56 (d, *J* = 7.7 Hz, 1H), 5.12 (t, *J* = 9.6 Hz, 1H), 3.81 (s, 1H), 3.56 (s, 1H), 3.07 (dd, *J* = 16.1, 10.5 Hz, 1H), 2.76 (dd, *J* = 16.1, 8.9 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ: 150.09, 146.95, 144.08, 129.22, 128.67, 128.21, 127.24, 127.04, 126.77, 125.82, 125.50, 124.75, 119.67, 109.79, 77.18, 66.86, 31.18.


(S)-2-(Indolin-2-yl)-1,3-diphenylpropan-2-ol (L2)



[*a*]_D²⁰ = -18.4 (c = 1.0, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ: 7.33-7.19 (m, 9H), 7.07 (d, *J* = 7.3 Hz, 1H), 6.98 (dd, *J* = 14.0, 6.4 Hz, 2H), 6.69 (t, *J* = 7.4 Hz, 1H), 6.49 (d, *J* = 7.7 Hz, 1H), 3.94 (t,


$J = 9.5$ Hz, 1H), 3.57 (s, 1H), 3.21-3.00 (m, 3H), 2.79 (s, 2H), 2.71 (d, $J = 13.8$ Hz, 1H), 2.42 (s, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ : 150.58, 137.52, 137.16, 130.82, 130.27, 128.48, 128.41, 128.26, 127.30, 126.67, 126.52, 124.52, 119.00, 109.52, 75.31, 65.83, 44.09, 42.21, 31.52.

(S)-2-(Indolin-2-yl)-1,3-bis(4-methoxyphenyl)propan-2-ol (L3)




$[a]_D^{20} = -10.5$ ($c = 0.9$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 7.21 (d, $J = 8.6$ Hz, 2H), 7.12 (d, $J = 8.6$ Hz, 2H), 7.06 (d, $J = 7.2$ Hz, 1H), 6.97 (t, $J = 7.6$ Hz, 1H), 6.84 (dd, $J = 10.9, 8.6$ Hz, 4H), 6.68 (t, $J = 7.3$ Hz, 1H), 6.51 (d, $J = 7.7$ Hz, 1H), 3.91 (t, $J = 9.5$ Hz, 1H), 3.80 (s, 3H), 3.79 (s, 3H), 3.07 (ddd, $J = 27.5, 18.4, 11.9$ Hz, 3H), 2.72 (s, 2H), 2.63 (d, $J = 14.0$ Hz, 1H), 2.34 (s, 1H), 1.61 (s, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ : 158.45, 158.33, 150.64, 131.72, 131.17, 129.39, 129.07, 128.48, 127.27, 124.52, 118.93, 113.91, 113.70, 109.47, 75.25, 65.73, 55.27, 55.24, 43.01, 41.08, 31.47.

(S)-1,3-bis(2-Fluorophenyl)-2-(indolin-2-yl)propan-2-ol (L4)




$[a]_D^{20} = +5.6$ ($c = 1.0$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 7.39 (td, $J = 7.6, 1.5$ Hz, 1H), 7.24-7.14 (m, 3H), 7.13-6.92 (m, 6H), 6.70 (t, $J = 7.4$ Hz, 1H), 6.60 (d, $J = 7.7$ Hz, 1H), 3.91 (t, $J = 9.3$ Hz, 1H), 3.13 (d, $J = 9.3$ Hz, 2H), 3.02 (dd, $J = 17.5, 14.4$ Hz, 2H), 2.83 (dd, $J = 14.0, 9.9$ Hz, 2H), 2.37 (s, 1H), 1.67 (s, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ : 161.70 ($^1J_{CF} = 243.5$ Hz), 161.60 ($^1J_{CF} = 243.5$ Hz), 150.67, 133.12 (d, $^2J_{CF} = 20.8$ Hz), 133.08 (d, $^2J_{CF} = 20.8$ Hz), 128.67, 128.50, 128.42, 128.33, 127.36, 124.61, 124.12, 124.04, 123.98, 119.03, 115.34 (d, $^2J_{CF} = 23.4$ Hz), 115.27 (d, $^2J_{CF} = 23.4$ Hz), 109.63, 76.15, 64.95, 35.33, 33.92, 31.43.

(S)-3-(Indolin-2-yl)-1,5-diphenylpentan-3-ol (L5)




$[a]_D^{20} = -44.8$ ($c = 0.65$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 7.39-7.29 (m, 4H), 7.29-7.19 (m, 6H), 7.11 (d, $J = 7.3$ Hz, 1H), 7.04 (t, $J = 7.6$ Hz, 1H), 6.77 (td, $J = 7.4, 0.9$ Hz, 1H), 6.67 (d, $J = 7.7$ Hz, 1H), 4.08 (dd, $J = 10.6, 9.2$ Hz, 1H), 3.84 (s, 1H), 3.19 (dd, $J = 15.5, 10.7$ Hz, 1H), 2.99 (dd, $J = 15.6, 9.1$ Hz, 1H), 2.93-2.61 (m, 4H), 2.46 (s, 1H), 2.11-1.74 (m, 4H). ^{13}C NMR (101 MHz, CDCl_3) δ : 150.33, 142.25, 142.09, 129.25, 128.59, 128.54, 128.31, 128.29, 127.28, 126.05, 126.03, 124.76, 119.70, 110.09, 73.64, 66.17, 39.73, 36.18, 30.27, 30.14, 30.00.

(S)-5-(Indolin-2-yl)nonan-5-ol (L6)




$[a]_D^{20} = -52.9$ ($c = 1.0$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 7.08 (d, $J = 7.3$ Hz, 1H), 7.01 (t, $J = 7.6$ Hz, 1H), 6.73 (td, $J = 7.4$, 0.7 Hz, 1H), 6.66 (d, $J = 7.7$ Hz, 1H), 3.95 (dd, $J = 10.8$, 9.0 Hz, 1H), 3.10 (dd, $J = 15.6$, 10.9 Hz, 1H), 2.90 (dd, $J = 15.6$, 9.0 Hz, 1H), 2.24 (s, 1H), 1.62-1.14 (m, 12H), 0.94 (td, $J = 7.1$, 4.6 Hz, 7H). ^{13}C NMR (101 MHz, CDCl_3) δ : 150.53, 129.51, 127.13, 124.70, 119.42, 109.88, 73.62, 66.43, 37.46, 34.04, 30.12, 25.82, 25.55, 23.43, 14.11, 14.03.

(S)-2-(1-Methylindolin-2-yl)-1,3-diphenylpropan-2-ol (L7)




$[a]_D^{20} = -2.6$ ($c = 1.0$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 7.33-7.14 (m, 9H), 7.06 (dd, $J = 16.2$, 7.7 Hz, 2H), 6.95 (dd, $J = 18.3$, 6.6 Hz, 1H), 6.64 (t, $J = 7.3$ Hz, 1H), 6.47 (d, $J = 7.8$ Hz, 1H), 3.41 (dd, $J = 10.2$, 8.3 Hz, 1H), 3.29 (dd, $J = 16.1$, 10.3 Hz, 1H), 3.16 (d, $J = 13.7$ Hz, 1H), 2.96 (dd, $J = 16.1$, 8.1 Hz, 1H), 2.90 (s, 3H), 2.82 (d, $J = 14.2$ Hz, 1H), 2.73 (dd, $J = 14.0$, 7.5 Hz, 2H), 1.66 (s, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ : 154.32, 136.99, 136.72, 131.09, 130.43, 128.25, 128.23, 127.88, 127.60, 126.56, 126.48, 123.92, 117.59, 107.83, 77.76, 71.67, 43.63, 40.53, 38.64, 32.19.

2-((2*S*)-octahydro-1*H*-indol-2-yl)-1,3-diphenylpropan-2-ol (L8)



$[a]_D^{20} = -1.3$ ($c = 0.62$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 7.40-7.09 (m, 10H), 3.82-3.54 (m, 1H), 3.24 (t, $J = 8.3$ Hz, 1H), 3.05-2.91 (m, 2H), 2.64 (t, $J = 10.7$ Hz, 3H), 2.03-1.88 (m, 2H), 1.78-1.10 (m, 10H). ^{13}C NMR (101 MHz, CDCl_3) δ : 138.69, 138.30, 130.75, 130.28, 128.55, 128.11, 128.02, 126.11, 73.99, 63.61, 55.95, 45.33, 43.10, 37.61, 31.06, 31.00, 27.91, 22.92, 22.82.


4-Nitro-*N*(((2*S*)-octahydro-1*H*-indol-2-yl)methyl)benzenesulfonamide (L9)²



$[a]_D^{20} = +7.0$ ($c = 1.3$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 8.36 (d, $J = 8.8$ Hz, 2H), 8.06 (d, $J = 8.8$ Hz, 2H), 3.60-3.32 (m, 3H), 3.18-3.07 (m, 2H), 2.92 (dd, $J = 12.4$, 7.4 Hz, 1H), 2.04 (dt, $J = 13.0$, 6.5 Hz, 1H), 1.99-1.87 (m, 1H), 1.66-1.36 (m, 6H), 1.35-1.16 (m, 3H). ^{13}C NMR (101 MHz,


CDCl_3) δ : 149.91, 146.42, 128.22, 124.30, 57.41, 56.57, 48.43, 38.17, 33.57, 29.65, 27.98, 23.10, 22.24.

(S)-diPhenyl(pyrrolidin-2-yl)methanol (L10)³



$[a]_D^{20} = -68.6$ ($c = 1.0$, CHCl_3). ^1H NMR (400 MHz, CDCl_3) δ : 7.66-7.35 (m, 4H), 7.32-6.92 (m, 6H), 4.56 (s, 1H), 4.25 (t, $J = 7.6$ Hz, 1H), 3.09-2.68 (m, 2H), 1.80-1.41 (m, 4H). ^{13}C NMR (101 MHz, CDCl_3) δ : 148.17, 145.41, 128.22, 127.96, 126.45, 126.34, 125.86, 125.53, 77.11, 64.49, 46.76, 26.28, 25.51.

(4*S*,4'*S*)-2,2'-(Propane-2,2-diyl)bis(4-isopropyl-4,5-dihydrooxazole) (L11)⁴




$[a]_D^{20} = -82.3$ ($c = 0.8$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 4.24-4.16 (m, 2H), 4.03-3.94 (m, 4H), 1.84-1.75 (m, 2H), 1.52 (s, 6H), 0.92 (d, $J = 6.8$ Hz, 6H), 0.86 (d, $J = 6.8$ Hz, 6H). ^{13}C NMR (101 MHz, CDCl_3) δ : 168.81, 71.52, 69.94, 38.59, 32.20, 24.45, 18.52, 17.36.

3. Synthesis of β,γ -unsaturated α -ketoesters **1a-f, 1h, 1j-k, 1m-n** and **1p**.


The β,γ -unsaturated α -ketoesters **1a-1f, 1h, 1j-k, 1m-n** and **1p** were prepared following the literature methods.⁵

(E)-Methyl 2-oxo-4-phenylbut-3-enoate (1a)



^1H NMR (400 MHz, CDCl_3) δ : 7.89 (d, $J = 16.1$ Hz, 1H), 7.64 (dd, $J = 7.4, 1.1$ Hz, 2H), 7.49-7.33 (m, 4H), 3.94 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ : 182.43, 162.56, 148.66, 133.99, 131.70, 129.10, 129.07, 120.48, 53.03.


(E)-Ethyl 2-oxo-4-phenylbut-3-enoate (1b)



^1H NMR (400 MHz, CDCl_3) δ : 7.85 (d, $J = 16.1$ Hz, 1H), 7.68-7.57 (m, 2H), 7.45-7.31 (m, 4H),


4.38 (q, $J = 7.1$ Hz, 2H), 1.40 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ : 182.92, 162.22, 148.47, 134.01, 131.63, 129.08, 129.03, 120.58, 62.50, 14.05.

(E)-isoPropyl 2-oxo-4-phenylbut-3-enoate (1c)




^1H NMR (400 MHz, CDCl_3) δ : 7.84 (d, $J = 16.1$ Hz, 1H), 7.62 (d, $J = 5.9$ Hz, 2H), 7.49-7.37 (m, 3H), 7.33 (d, $J = 16.1$ Hz, 1H), 5.23 (dt, $J = 16.3, 6.2$ Hz, 1H), 1.39 (s, 6H). ^{13}C NMR (101 MHz, CDCl_3) δ : 183.32, 161.92, 148.21, 134.11, 131.53, 129.06, 128.97, 120.79, 70.65, 21.64.

(E)-Methyl 4-(2-fluorophenyl)-2-oxobut-3-enoate (1d)




^1H NMR (400 MHz, CDCl_3) δ : 8.01 (d, $J = 16.3$ Hz, 1H), 7.65 (td, $J = 7.7, 1.6$ Hz, 1H), 7.49-7.39 (m, 2H), 7.24-7.17 (m, 1H), 7.14 (m, $J = 10.5, 8.3, 1.0$ Hz, 1H), 3.95 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ : 182.48, 162.40, 161.97 (d, $J = 256.2$ Hz), 140.91 (d, $J = 3.1$ Hz), 133.15 (d, $J = 8.9$ Hz), 129.55 (d, $J = 2.4$ Hz), 124.65 (d, $J = 3.7$ Hz), 122.64 (d, $J = 6.6$ Hz), 122.21 (d, $J = 11.3$ Hz), 116.42 (d, $J = 21.8$ Hz), 53.04.

(E)-Methyl 4-(3-fluorophenyl)-2-oxobut-3-enoate (1e)




^1H NMR (400 MHz, CDCl_3) δ : 7.83 (d, $J = 16.1$ Hz, 1H), 7.43-7.30 (m, 4H), 7.19-7.12 (m, 1H), 3.95 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ : 182.14, 163.01 (d, $J = 247.7$ Hz), 162.27, 146.92 (d, $J = 2.7$ Hz), 136.18 (d, $J = 7.6$ Hz), 130.67 (d, $J = 8.2$ Hz), 125.09 (d, $J = 2.8$ Hz), 121.61, 118.50 (d, $J = 21.5$ Hz), 115.04 (d, $J = 22.0$ Hz), 53.09.

(E)-Methyl 4-(4-fluorophenyl)-2-oxobut-3-enoate (1f)




^1H NMR (400 MHz, CDCl_3) δ : 7.84 (d, $J = 16.1$ Hz, 1H), 7.64 (dd, $J = 8.6, 5.5$ Hz, 2H), 7.31 (d, $J = 16.1$ Hz, 1H), 7.12 (t, $J = 8.6$ Hz, 2H), 3.94 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ : 182.15, 164.74 (d, $J = 253.9$ Hz), 162.47, 147.18, 131.11 (d, $J = 8.8$ Hz), 130.31 (d, $J = 3.4$ Hz), 120.17, 116.38 (d, $J = 22.1$ Hz), 53.04.

(E)-Methyl 4-(4-chlorophenyl)-2-oxobut-3-enoate (1h)




¹H NMR (400 MHz, CDCl₃) δ: 7.83 (d, *J* = 16.1 Hz, 1H), 7.57 (d, *J* = 8.6 Hz, 2H), 7.41 (d, *J* = 8.5 Hz, 2H), 7.35 (d, *J* = 16.1 Hz, 1H), 3.94 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ: 182.13, 162.39, 146.96, 137.75, 132.49, 130.15, 129.44, 120.87, 53.06.

(E)-Methyl 2-oxo-4-(*p*-tolyl)but-3-enoate (1j)




¹H NMR (400 MHz, CDCl₃) δ: 7.86 (d, *J* = 16.1 Hz, 1H), 7.54 (d, *J* = 8.0 Hz, 2H), 7.32 (d, *J* = 16.1 Hz, 1H), 7.23 (d, *J* = 7.9 Hz, 2H), 3.93 (s, 3H), 2.40 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ: 182.45, 162.70, 148.76, 142.56, 131.33, 129.86, 129.14, 119.51, 52.95, 21.63.

(E)-Methyl 4-([1,1'-biphenyl]-4-yl)-2-oxobut-3-enoate (1k)




¹H NMR (400 MHz, CDCl₃) δ: 7.92 (d, *J* = 16.1 Hz, 1H), 7.73-7.59 (m, 6H), 7.42 (m, *J* = 13.5, 10.5, 5.7 Hz, 4H), 3.95 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ: 182.32, 162.62, 148.17, 144.48, 139.84, 132.94, 129.63, 128.97, 128.16, 127.71, 127.09, 120.26, 53.02.

(E)-Methyl 4-(3-methoxyphenyl)-2-oxobut-3-enoate (1m)




¹H NMR (400 MHz, CDCl₃) δ: 7.84 (d, *J* = 16.1 Hz, 1H), 7.33 (dd, *J* = 12.0, 4.0 Hz, 2H), 7.23 (d, *J* = 7.6 Hz, 1H), 7.14 (s, 1H), 7.07-6.94 (m, 1H), 3.94 (s, 3H), 3.85 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ: 182.41, 162.56, 160.04, 148.54, 135.34, 130.06, 121.85, 120.77, 117.77, 113.57, 55.36, 52.96.

(E)-Methyl 4-(4-methoxyphenyl)-2-oxobut-3-enoate (1n)



¹H NMR (400 MHz, CDCl₃) δ: 7.86 (d, *J* = 16.0 Hz, 1H), 7.61 (d, *J* = 8.7 Hz, 2H), 7.26 (d, *J* = 16.0 Hz, 1H), 6.95 (d, *J* = 8.8 Hz, 2H), 3.94 (s, 3H), 3.87 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ: 182.26, 162.88, 162.69, 148.52, 131.09, 126.83, 118.16, 114.63, 55.47, 52.91.


(E)-Methyl 4-(furan-2-yl)-2-oxobut-3-enoate (1p)



¹H NMR (400 MHz, CDCl₃) δ: 7.63 (d, *J* = 15.8 Hz, 1H), 7.60-7.56 (m, 1H), 7.26-7.19 (m, 1H), 6.83 (d, *J* = 3.5 Hz, 1H), 6.55 (dd, *J* = 3.4, 1.7 Hz, 1H), 3.92 (d, *J* = 0.4 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ: 181.96, 162.41, 151.06, 146.37, 133.67, 118.60, 118.04, 113.17, 52.94.


4. Synthesis of β,γ-unsaturated α-ketoesters 1g, 1i, 1l and 1o.

a) Preparation of aryl acetal derivatives^{5a}




A solution of aldehyde (50 mmol), *p*-toluenesulfonic acid monohydrate (2.5 mmol) and trimethyl orthoformate (0.5 mol) in dry methanol (100 mL) was heated to reflux for 24 h. Part of the solvent was evaporated *in vacuo*, then Et₂O (125 mL) was added to the residue (*ca.* 25 mL), and the mixture was washed with saturated NaHCO₃ solution (125 mL). The organic layer was separated, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash chromatography.

b) Preparation of methyl 2-((trimethylsilyl)oxy)acrylate⁶



TEA (18.8 mL, 13.66 g, 135 mmol) was added dropwise to a mixture of methyl pyruvate (10.21 g, 100 mmol) and TMSCl (14.2 mL, 12.17 g, 112 mmol) in THF (100 mL) under N₂. After 3.5 h, pentane (150 mL) was added, and the reaction mixture was filtered. The filtrate was washed with water (50 mL) and brine (50 mL) in turn, dried over Na₂SO₄ and evaporated to give methyl 2-((trimethylsilyl)oxy)acrylate as a clear liquid (14.8 g, 85% yield), which was used without further purification.


c) Preparation of methyl 2-oxo-4-arylbut-3-enoate^{5a,7}



To a mixture of acetal (20 mmol) and methyl 2-((trimethylsilyl)oxy)acrylate (24 mmol) in dry dichloromethane (100 mL) was added boron trifluoridediethyl ether (22 mmol) dropwise under N₂


at -78 °C. The reaction mixture was warmed to 0 °C and stirred at the same temperature for 2 h. Saturated NaHCO₃ was added, the mixture was extracted with CH₂Cl₂. The organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford crude γ -alkoxy- α -oxo ester, which was dissolved in toluene (100 mL). Then silica gel (30 g) was added and the mixture was heated at 110 °C with vigorous stirring for 12 h. After being cooled to room temperature, the mixture was filtered and the residue was washed with DCM for several times. The filtrate was combined, concentrated to give the crude β,γ -unsaturated α -ketoester. The purification was carried out by flash column chromatography with petroleum ether/ethyl acetate to afford yellow oil or solid.

(E)-Methyl 4-(2-chlorophenyl)-2-oxobut-3-enoate (1g)




¹H NMR (400 MHz, CDCl₃) δ: 8.31 (d, *J* = 16.2 Hz, 1H), 7.75 (d, *J* = 7.5 Hz, 1H), 7.50-7.28 (m, 4H), 3.95 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ: 182.25, 162.37, 144.05, 136.19, 132.26, 130.44, 127.97, 127.21, 122.73, 99.99, 53.05.

(E)-Methyl 4-(2-bromophenyl)-2-oxobut-3-enoate (1i)




¹H NMR (400 MHz, CDCl₃) δ: 8.28 (d, *J* = 16.1 Hz, 1H), 7.75 (dd, *J* = 7.8, 1.5 Hz, 1H), 7.66 (d, *J* = 8.0 Hz, 1H), 7.38 (t, *J* = 7.5 Hz, 1H), 7.34-7.31 (m, 1H), 7.31-7.28 (m, 1H), 3.96 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ: 182.19, 162.36, 146.70, 133.74, 132.38, 129.39, 128.10, 127.84, 126.65, 122.96, 53.08.

(E)-Methyl 4-(2-methoxyphenyl)-2-oxobut-3-enoate (1l)



¹H NMR (400 MHz, CDCl₃) δ: 8.21 (d, *J* = 16.2 Hz, 1H), 7.62 (d, *J* = 7.7 Hz, 1H), 7.49-7.35 (m, 2H), 7.05-6.90 (m, 2H), 3.93 (s, 3H), 3.91 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ: 183.05, 162.95, 159.29, 144.15, 133.11, 129.53, 123.02, 120.92, 120.84, 111.35, 55.57, 52.87.

(E)-Methyl 4-(2,5-dimethoxyphenyl)-2-oxobut-3-enoate (1o)




¹H NMR (400 MHz, CDCl₃) δ: 8.21 (d, *J* = 16.2 Hz, 1H), 7.40 (d, *J* = 16.2 Hz, 1H), 7.15 (d, *J* =

3.0 Hz, 1H), 7.01 (dd, J = 9.0, 3.0 Hz, 1H), 6.89 (d, J = 9.0 Hz, 1H), 3.95 (s, 3H), 3.88 (s, 3H), 3.82 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ : 182.89, 162.90, 153.89, 153.53, 143.84, 123.42, 120.96, 119.30, 113.22, 112.62, 56.09, 55.84, 52.89.

5. Preparation of 2-vinylindoles 2


The 2-vinylindoles were prepared following the literature methods.⁸

(E)-1-Methyl-2-styryl-1*H*-indole (2a)




^1H NMR (400 MHz, CDCl_3) δ : 7.59 (d, J = 7.9 Hz, 1H), 7.53 (d, J = 8.1 Hz, 2H), 7.38 (t, J = 7.4 Hz, 2H), 7.33-7.27 (m, 2H), 7.21 (d, J = 7.0 Hz, 1H), 7.18 (s, 2H), 7.10 (t, J = 7.4 Hz, 1H), 6.81 (s, 1H), 3.82 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ : 138.42, 138.18, 137.18, 130.93, 128.78, 128.00, 127.85, 126.45, 121.78, 120.43, 119.91, 117.09, 109.14, 99.08, 29.92.

(E)-2-(4-Bromostyryl)-1-methyl-1*H*-indole (2b)



^1H NMR (400 MHz, CDCl_3) δ : 7.59 (d, J = 7.9 Hz, 1H), 7.49 (d, J = 8.4 Hz, 2H), 7.38 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 8.2 Hz, 1H), 7.20 (dd, J = 15.0, 7.1 Hz, 1H), 7.15-7.05 (m, 3H), 6.80 (s, 1H), 3.81 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ : 138.25, 137.98, 136.13, 131.87, 129.44, 127.93, 127.86, 121.99, 121.51, 120.51, 120.00, 117.75, 109.17, 99.44, 29.92.

(E)-1-Methyl-2-(4-methylstyryl)-1*H*-indole (2c)




^1H NMR (400 MHz, CDCl_3) δ : 7.57 (d, J = 7.8 Hz, 1H), 7.41 (d, J = 8.1 Hz, 2H), 7.26-7.04 (m, 7H), 6.76 (s, 1H), 3.76 (s, 3H), 2.36 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ : 138.67, 138.14, 137.85, 134.44, 130.97, 129.52, 128.08, 126.40, 121.65, 120.37, 119.87, 116.10, 109.12, 98.78, 29.90, 21.32.

6. General procedure for the asymmetric Diels–Alder reaction

To a 10 mL tube was added chiral ligand **L2** (3.3 mg, 0.01 mmol), enone **1** (0.12 mmol), $\text{Cu}(\text{OTf})_2$ (3.6 mg, 0.01 mmol) and 1.5 mL DCM (containing 0.1mmol H_2O) under N_2 . The solution was


stirred at 30 °C for 30 min, then 2-vinylindole **2** (0.8 mmol) was added. After completion of the reaction (about 10 min), the mixture was quenched with saturated NaHCO₃ solution (1 mL) and extracted with DCM (3×3 mL). The DCM layer was combined, dried over anhydrous Na₂SO₄. After filtration, the solvent was removed under reduced pressure to give the crude product, which was purified by column chromatography on silica gel to provide pure **3**.

Methyl 2-((2*R*,2*R*,4*R*)-9-methyl-2,4-diphenyl-2,3,4,9-tetrahydro-1*H*-carbazol-3-yl)-2-oxoacetate (3a)




Yield: 90%, pale yellow solid. HPLC: Chiralpak AD-H (hexane/*i*-PrOH = 95/5, flow rate 0.5 mL/min, λ = 220 nm), t_{major} = 21.34 min, t_{minor} = 26.97 min, 95% ee. $[a]_D^{25} = -42.6$ (c = 0.76, CH₂Cl₂). mp 150-153 °C. ¹H NMR (400 MHz, CDCl₃) δ : 7.34-7.18 (m, 9H), 7.18-7.12 (m, 1H), 7.10 (dd, *J* = 7.8, 1.4 Hz, 2H), 6.95-6.86 (m, 2H), 4.63 (d, *J* = 4.1 Hz, 1H), 4.17 (dd, *J* = 4.1, 3.0 Hz, 1H), 3.76 (s, 3H), 3.73 (s, 3H), 3.67-3.56 (m, 2H), 3.25 (q, *J* = 9.6 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ : 193.35, 161.47, 143.56, 141.37, 137.68, 136.17, 128.67, 128.52, 128.43, 128.02, 127.04, 126.68, 126.58, 121.02, 118.96, 118.83, 108.67, 107.78, 56.22, 52.92, 39.11, 38.07, 29.33, 25.60. HRMS (ESI) *m/z* calcd. for C₂₈H₂₆NO₃ [M+H]⁺: 424.1907, found: 424.1905.

Ethyl 2-((2*R*,3*R*,4*R*)-9-methyl-2,4-diphenyl-2,3,4,9-tetrahydro-1*H*-carbazol-3-yl)-2-oxoacetate (3b)




Yield: 89%, pale yellow solid. HPLC: Chiralpak AD-H (hexane/*i*-PrOH = 98/2, flow rate 0.6 mL/min, λ = 220 nm), t_{major} = 25.88 min, t_{minor} = 37.77 min, 53% ee. $[a]_D^{25} = -32.5$ (c = 0.67, CH₂Cl₂). mp 172-176 °C. ¹H NMR (400 MHz, CDCl₃) δ : 7.36-7.06 (m, 12H), 6.92 (dt, *J* = 14.5, 7.3 Hz, 2H), 4.64 (d, *J* = 3.6 Hz, 1H), 4.31-4.07 (m, 3H), 3.73 (s, 3H), 3.68-3.57 (m, 2H), 3.32-3.07 (m, 1H), 1.28 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ : 193.77, 161.17, 143.65, 141.51, 137.70, 136.29, 128.82, 128.64, 128.49, 128.41, 128.02, 126.98, 126.64, 121.00, 118.95, 118.78, 108.65, 107.71, 62.43, 56.11, 39.20, 37.98, 29.30, 25.53, 13.90. HRMS (ESI) *m/z* calcd. for C₂₉H₂₈NO₃ [M+H]⁺: 438.2064, found: 438.2066.

isoPropyl 2-((2*R*,3*R*,4*R*)-9-methyl-2,4-diphenyl-2,3,4,9-tetrahydro-1*H*-carbazol-3-yl)-2-oxoacetate (3c)




Yield: 95%, pale yellow solid. HPLC: Chiralpak AD-H (hexane/*i*-PrOH = 95/5, flow rate 0.5 mL/min, λ = 220 nm), t_{major} = 12.86 min, t_{minor} = 18.88 min, 34% ee. $[\alpha]_D^{25} = -21.5$ ($c = 0.86$, CH_2Cl_2). mp 115-118 °C. ^1H NMR (400 MHz, CDCl_3) δ : 7.39-7.20 (m, 9H), 7.20-7.14 (m, 3H), 7.03-6.92 (m, 2H), 5.15-5.04 (m, 1H), 4.69 (d, $J = 3.6$ Hz, 1H), 4.21 (t, $J = 3.0$ Hz, 1H), 3.77 (s, 3H), 3.71 (t, $J = 8.0$ Hz, 1H), 3.68-3.64 (m, 1H), 3.26 (dd, $J = 14.8, 4.5$ Hz, 1H), 1.31 (dd, $J = 10.6, 6.3$ Hz, 6H). ^{13}C NMR (101 MHz, CDCl_3) δ : 194.13, 160.85, 143.73, 141.62, 137.70, 136.39, 128.65, 128.52, 128.43, 128.05, 126.98, 126.66, 121.01, 118.97, 118.76, 108.69, 107.70, 70.77, 56.01, 39.26, 37.97, 29.33, 25.53, 21.56. HRMS (ESI) m/z calcd. for $\text{C}_{30}\text{H}_{30}\text{NO}_3$ [$\text{M}+\text{H}]^+$: 452.2220, found: 452.2224.

Methyl 2-((2*R*,3*R*,4*S*)-4-(2-fluorophenyl)-9-methyl-2-phenyl-2,3,4,9-tetrahydro-1*H*-carbazol-3-yl)-2-oxoacetate (3d)




Yield: 96%, pale yellow solid. HPLC: Chiralcel OD-H (hexane/*i*-PrOH = 95/5, flow rate 0.5 mL/min, λ = 220 nm), t_{major} = 22.68 min, t_{minor} = 26.33 min, 93% ee. $[\alpha]_D^{25} = -23.9$ ($c = 0.82$, CH_2Cl_2). mp 198-201 °C. ^1H NMR (400 MHz, CDCl_3) δ : 7.30 (d, $J = 8.2$ Hz, 1H), 7.28-7.05 (m, 8H), 7.02-6.86 (m, 4H), 4.88 (d, $J = 3.6$ Hz, 1H), 4.23 (dd, $J = 20.4, 16.7$ Hz, 1H), 3.74 (d, $J = 13.2$ Hz, 3H), 3.68 (s, 3H), 3.67-3.61 (m, 1H), 3.52 (dd, $J = 16.0, 9.1$ Hz, 1H), 3.23 (dt, $J = 22.1, 11.1$ Hz, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ : 194.27, 161.84, 160.72 (${}^1J_{CF} = 247.2$ Hz), 140.97, 137.69, 136.28, 130.97, 130.13 (d, ${}^2J_{CF} = 13.7$ Hz), 128.58, 128.53, 127.87, 127.17, 126.26, 123.99, 121.12, 119.06, 118.44, 115.6 (d, ${}^2J_{CF} = 21.9$ Hz), 108.76, 106.82, 53.83, 52.77, 38.45, 33.03, 29.34, 25.33. HRMS (ESI) m/z calcd. for $\text{C}_{28}\text{H}_{25}\text{FNO}_3$ [$\text{M}+\text{H}]^+$: 442.1813, found: 442.1814.

Methyl 2-((2*R*,3*R*,4*R*)-4-(3-fluorophenyl)-9-methyl-2-phenyl-2,3,4,9-tetrahydro-1*H*-carbazol-3-yl)-2-oxoacetate (3e)




Yield: 94%, pale yellow solid. HPLC: Chiralpak AD-H (hexane/*i*-PrOH = 96/4, flow rate 0.5 mL/min, λ = 220 nm), t_{major} = 23.38 min, t_{minor} = 27.66 min, 50% ee. $[\alpha]_D^{25} = -36.3$ ($c = 0.81$, CH_2Cl_2). mp 140-145 °C. ^1H NMR (400 MHz, CDCl_3) δ : 7.31 (d, $J = 7.8$ Hz, 1H), 7.24-7.07 (m, 8H), 6.99 (d, $J = 10.1$ Hz, 1H), 6.96-6.88 (m, 3H), 4.62 (d, $J = 4.1$ Hz, 1H), 4.18-4.10 (m, 1H), 3.76 (s, 3H), 3.73 (s, 3H), 3.65-3.56 (m, 2H), 3.26 (q, $J = 10.3$ Hz, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ : 193.04, 163.01 (d, $J = 245.6$ Hz), 161.36, 146.44 (d, $J = 6.6$ Hz), 141.10, 137.72, 136.23, 129.89 (d, $J = 8.3$ Hz), 128.60, 128.01, 127.18, 126.40, 124.41, 121.18, 119.14, 118.70, 115.65 (d, $J = 21.7$ Hz), 113.73 (d, $J = 21.2$ Hz), 108.81, 107.29, 56.10, 53.01, 38.89, 38.20, 29.36, 25.62. HRMS (ESI) m/z calcd. for $\text{C}_{28}\text{H}_{25}\text{FNO}_3$ [M+H] $^+$: 442.1813, found: 442.1818.

Methyl 2-((2*R*,3*R*,4*R*)-4-(4-fluorophenyl)-9-methyl-2-phenyl-2,3,4,9-tetrahydro-1*H*-carbazol-3-yl)-2-oxoacetate (3f)



Yield: 86%, pale yellow solid. HPLC: Chiralpak AD-H (hexane/*i*-PrOH = 94/6, flow rate 0.5 mL/min, λ = 220 nm), t_{major} = 18.88 min, t_{minor} = 22.82 min, 52% ee. $[\alpha]_D^{25} = -38.1$ ($c = 0.70$, CH_2Cl_2). mp 179-183 °C. ^1H NMR (400 MHz, CDCl_3) δ : 7.34 (d, $J = 8.2$ Hz, 1H), 7.31-7.15 (m, 6H), 7.11 (dd, $J = 7.7, 1.6$ Hz, 2H), 7.02-6.87 (m, 4H), 4.62 (d, $J = 4.6$ Hz, 1H), 4.14 (dd, $J = 4.6, 3.1$ Hz, 1H), 3.80 (s, 3H), 3.76 (s, 3H), 3.69-3.56 (m, 2H), 3.29 (dd, $J = 15.1, 4.6$ Hz, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ : 193.15, 161.71 ($^1J_{CF} = 246.5$ Hz), 161.40, 141.13, 139.18, 137.69, 136.06, 130.24, 128.56, 127.99, 127.14, 126.38, 121.12, 119.05, 118.77, 108.75, 107.83, 56.38, 52.98, 38.31, 38.21, 29.33, 25.74. HRMS (ESI) m/z calcd. for $\text{C}_{28}\text{H}_{25}\text{FNO}_3$ [M+H] $^+$: 442.1813, found: 442.1818.


Methyl 2-((2*R*,3*R*,4*S*)-4-(2-chlorophenyl)-9-methyl-2-phenyl-2,3,4,9-tetrahydro-1*H*-carbazol-3-yl)-2-oxoacetate (3g)



Yield: 91%, pale yellow solid. HPLC: Chiralpak AD-H (hexane/*i*-PrOH = 90/10, flow rate 0.8 mL/min, λ = 220 nm), t_{major} = 13.05 min, t_{minor} = 33.68 min, 67% ee. $[\alpha]_D^{25} = -12.8$ ($c = 0.74$, CH_2Cl_2). mp 180-184 °C. ^1H NMR (400 MHz, CDCl_3) δ : 7.46 (d, $J = 7.6$ Hz, 1H), 7.35-7.11 (m, 8H), 7.07 (t, $J = 7.3$ Hz, 1H), 7.02-6.89 (m, 3H), 5.00 (s, 1H), 4.15 (s, 1H), 3.75 (s, 3H), 3.55 (s, 4H), 3.42 (dd, $J = 16.0, 10.6$ Hz, 1H), 3.19 (d, $J = 12.9$ Hz, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ :


195.42, 162.22, 140.78, 140.57, 137.76, 136.48, 133.70, 130.67, 129.93, 128.57, 128.20, 127.77, 127.23, 126.77, 126.23, 121.18, 119.09, 118.57, 108.76, 107.19, 53.29, 52.58, 38.45, 36.64, 29.34, 24.53. HRMS (ESI) m/z calcd. for $C_{28}H_{25}ClNO_3$ [M+H]⁺: 458.1517, found: 458.1518.

Methyl 2-((2*R*,3*R*,4*R*)-4-(4-chlorophenyl)-9-methyl-2-phenyl-2,3,4,9-tetrahydro-1*H*-carbazol-3-yl)-2-oxoacetate (3h)




Yield: 84%, pale yellow solid. HPLC: Chiralpak AD-H (hexane/*i*-PrOH = 95/5, flow rate 0.5 mL/min, λ = 220 nm), t_{major} = 28.32 min, t_{minor} = 31.49 min, 56% ee. $[a]_D^{25}$ = -41.7 (c = 0.70, CH_2Cl_2). mp 170-176 °C. ¹H NMR (400 MHz, $CDCl_3$) δ : 7.31 (d, J = 8.2 Hz, 1H), 7.26-7.21 (m, 6H), 7.17 (ddd, J = 9.5, 8.5, 3.8 Hz, 2H), 7.08 (dd, J = 7.7, 1.6 Hz, 2H), 6.91 (ddd, J = 16.3, 11.7, 4.2 Hz, 2H), 4.58 (d, J = 4.6 Hz, 1H), 4.11 (dd, J = 4.6, 3.1 Hz, 1H), 3.77 (s, 3H), 3.74 (s, 3H), 3.60 (dd, J = 20.7, 7.2 Hz, 2H), 3.27 (dd, J = 14.3, 3.7 Hz, 1H). ¹³C NMR (101 MHz, $CDCl_3$) δ : 193.05, 161.36, 142.11, 141.04, 137.70, 136.13, 132.46, 130.13, 128.59, 128.00, 127.19, 126.34, 121.18, 119.12, 118.76, 108.79, 107.51, 56.24, 53.02, 38.48, 38.26, 29.36, 25.73. HRMS (ESI) m/z calcd. for $C_{28}H_{25}ClNO_3$ [M+H]⁺: 458.1517, found: 458.1518.

Methyl 2-((2*R*,3*R*,4*S*)-4-(2-bromophenyl)-9-methyl-2-phenyl-2,3,4,9-tetrahydro-1*H*-carbazol-3-yl)-2-oxoacetate (3i)




Yield: 80%, pale yellow solid. HPLC: Chiralpak AD-H (hexane/*i*-PrOH = 90/10, flow rate 0.8 mL/min, λ = 220 nm), t_{major} = 15.00 min, t_{minor} = 32.64 min, 71% ee. $[a]_D^{25}$ = -8.2 (c = 0.80, CH_2Cl_2). mp 143-147 °C. ¹H NMR (400 MHz, $CDCl_3$) δ : 7.71-7.62 (m, 1H), 7.35-7.19 (m, 4H), 7.14 (ddd, J = 16.7, 7.2, 2.6 Hz, 5H), 6.95 (dt, J = 14.5, 7.3 Hz, 3H), 4.97 (s, 1H), 4.13 (s, 1H), 3.74 (s, 3H), 3.63-3.54 (m, 1H), 3.49 (s, 3H), 3.36 (dd, J = 15.8, 11.4 Hz, 1H), 3.17 (dd, J = 16.0, 5.1 Hz, 1H). ¹³C NMR (101 MHz, $CDCl_3$) δ : 195.64, 162.18, 142.31, 140.66, 137.77, 136.43, 133.23, 130.72, 128.58, 128.53, 127.77, 127.42, 127.28, 126.22, 124.53, 121.21, 119.11, 118.69, 108.77, 107.48, 53.64, 52.57, 39.27, 38.47, 29.36, 24.25. HRMS (ESI) m/z calcd. for $C_{28}H_{25}BrNO_3$ [M+H]⁺: 502.1012, found: 502.1013.

Methyl 2-((2*R*,3*R*,4*R*)-9-methyl-2-phenyl-4-(*p*-tolyl)-2,3,4,9-tetrahydro-1*H*-carbazol-3-yl)-2-oxoacetate (3j)




Yield: 77%, pale yellow solid. HPLC: Chiralpak AD-H (hexane/*i*-PrOH = 95/5, flow rate 0.5 mL/min, λ = 220 nm), t_{major} = 21.14 min, t_{minor} = 30.94 min, 59% ee. $[\alpha]_D^{25} = -48.3$ ($c = 0.77$, CH_2Cl_2). mp 140-147 °C. ^1H NMR (400 MHz, CDCl_3) δ : 7.30 (d, $J = 8.2$ Hz, 1H), 7.25-7.05 (m, 10H), 6.92 (dt, $J = 14.1$, 7.2 Hz, 2H), 4.60 (d, $J = 3.8$ Hz, 1H), 4.18-4.10 (m, 1H), 3.75 (s, 3H), 3.73 (s, 3H), 3.66-3.57 (m, 2H), 3.28-3.15 (m, 1H), 2.31 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ : 193.48, 161.51, 141.50, 140.54, 137.68, 136.15, 129.15, 128.84, 128.51, 128.05, 127.01, 126.65, 120.99, 118.95, 118.88, 108.66, 107.92, 56.31, 52.91, 38.76, 38.03, 29.33, 25.56, 21.10. HRMS (ESI) m/z calcd. for $\text{C}_{29}\text{H}_{28}\text{NO}_3$ [$\text{M}+\text{H}]^+$: 438.2064, found: 438.2063.

Methyl 2-((2*R*,3*R*,4*R*)-4-([1,1'-biphenyl]-4-yl)-9-methyl-2-phenyl-2,3,4,9-tetrahydro-1*H*-carbazol-3-yl)-2-oxoacetate (3k)



Yield: 68%, pale yellow solid. HPLC: Chiralpak AD-H (hexane/*i*-PrOH = 93/7, flow rate 0.5 mL/min, λ = 210 nm), t_{major} = 41.16 min, t_{minor} = 23.45 min, 57% ee. $[\alpha]_D^{25} = -65.0$ ($c = 0.65$, CH_2Cl_2). mp 167-174 °C. ^1H NMR (400 MHz, CDCl_3) δ : 7.64-7.58 (m, 2H), 7.54 (d, $J = 8.2$ Hz, 2H), 7.48-7.31 (m, 7H), 7.29-7.20 (m, 2H), 7.16 (dd, $J = 9.1$, 7.4 Hz, 3H), 7.01 (d, $J = 7.6$ Hz, 1H), 6.95 (t, $J = 7.3$ Hz, 1H), 4.70 (d, $J = 4.1$ Hz, 1H), 4.28-4.20 (m, 1H), 3.80 (s, 3H), 3.78 (s, 3H), 3.67 (dd, $J = 21.0$, 7.3 Hz, 2H), 3.30 (dd, $J = 14.0$, 3.6 Hz, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ : 193.32, 161.45, 142.67, 141.35, 140.88, 139.42, 137.69, 136.18, 129.07, 128.72, 128.53, 128.02, 127.11, 127.06, 126.99, 126.58, 121.06, 119.00, 118.87, 108.70, 107.72, 56.18, 52.94, 38.82, 38.13, 29.34, 25.61. HRMS (ESI) m/z calcd. for $\text{C}_{34}\text{H}_{30}\text{NO}_3$ [$\text{M}+\text{H}]^+$: 500.2220, found: 500.2220.


Methyl 2-((2*R*,3*R*,4*S*)-4-(2-methoxyphenyl)-9-methyl-2-phenyl-2,3,4,9-tetrahydro-1*H*-carbazol-3-yl)-2-oxoacetate (3l)



Yield: 80%, yellow solid. HPLC: Chiralpak AD-H (hexane/*i*-PrOH = 95/5, flow rate 0.6 mL/min,


$\lambda = 220$ nm), $t_{\text{major}} = 18.46$ min, $t_{\text{minor}} = 21.14$ min, 87% ee. $[\alpha]_D^{25} = +6.7$ ($c = 0.72$, CH_2Cl_2). mp 167-171 °C. ^1H NMR (400 MHz, CDCl_3) δ : 7.31 (d, $J = 8.2$ Hz, 1H), 7.28-7.23 (m, 1H), 7.23-7.11 (m, 6H), 7.04 (d, $J = 7.7$ Hz, 1H), 6.98-6.90 (m, 2H), 6.82 (dd, $J = 7.5, 1.7$ Hz, 1H), 6.74 (td, $J = 7.4, 0.9$ Hz, 1H), 4.92 (s, 1H), 4.12 (dd, $J = 3.3, 1.8$ Hz, 1H), 3.91 (s, 3H), 3.74 (s, 3H), 3.63 (s, 3H), 3.57-3.43 (m, 2H), 3.11 (dd, $J = 15.2, 4.5$ Hz, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ : 196.05, 162.80, 156.68, 141.75, 137.74, 137.00, 131.37, 129.93, 128.46, 127.92, 127.82, 126.89, 126.66, 120.91, 120.25, 118.82, 118.69, 110.30, 108.63, 106.93, 55.31, 52.86, 52.44, 38.30, 33.72, 29.30, 24.80. HRMS (ESI) m/z calcd. for $\text{C}_{29}\text{H}_{28}\text{NO}_4$ [$\text{M}+\text{H}]^+$: 454.2013, found: 454.2010.

Methyl 2-((2*R*,3*R*,4*R*)-4-(3-methoxyphenyl)-9-methyl-2-phenyl-2,3,4,9-tetrahydro-1*H*-carbazol-3-yl)-2-oxoacetate (3m)



Yield: 84%, pale yellow solid. HPLC: Chiralpak AD-H (hexane/*i*-PrOH = 98/2, flow rate 0.8 mL/min, $\lambda = 220$ nm), $t_{\text{major}} = 36.73$ min, $t_{\text{minor}} = 27.95$ min, 58% ee. $[\alpha]_D^{25} = -38.3$ ($c = 0.78$, CH_2Cl_2). mp 80-82 °C. ^1H NMR (400 MHz, CDCl_3) δ : 7.30 (d, $J = 8.2$ Hz, 1H), 7.20 (ddd, $J = 13.2, 7.9, 4.3$ Hz, 4H), 7.12 (dd, $J = 8.0, 6.6$ Hz, 3H), 7.00-6.86 (m, 4H), 6.77 (dd, $J = 7.9, 2.1$ Hz, 1H), 4.61 (d, $J = 3.9$ Hz, 1H), 4.17 (dd, $J = 4.8, 2.2$ Hz, 1H), 3.76 (s, 3H), 3.75 (s, 3H), 3.73 (s, 3H), 3.66-3.58 (m, 2H), 3.23 (q, $J = 10.4$ Hz, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ : 193.35, 161.46, 159.68, 145.37, 141.41, 137.70, 136.14, 129.35, 128.50, 128.03, 127.01, 126.63, 121.11, 121.00, 118.97, 118.80, 114.90, 111.68, 108.64, 107.64, 56.09, 55.17, 52.88, 39.20, 38.09, 29.30, 25.52. HRMS (ESI) m/z calcd. for $\text{C}_{29}\text{H}_{28}\text{NO}_4$ [$\text{M}+\text{H}]^+$: 454.2013, found: 454.2014.


Methyl 2-((2*R*,3*R*,4*R*)-4-(4-methoxyphenyl)-9-methyl-2-phenyl-2,3,4,9-tetrahydro-1*H*-carbazol-3-yl)-2-oxoacetate (3n)



Yield: 86%, pale yellow solid. HPLC: Chiralpak AD-H (hexane/*i*-PrOH = 90/10, flow rate 0.4mL/min, $\lambda = 220$ nm), $t_{\text{major}} = 32.85$ min, $t_{\text{minor}} = 26.14$ min, 78% ee. $[\alpha]_D^{25} = -56.7$ ($c = 0.78$, CH_2Cl_2). mp 188-191 °C. ^1H NMR (400 MHz, CDCl_3) δ : 7.31 (d, $J = 8.2$ Hz, 1H), 7.24-7.08 (m, 8H), 6.97-6.88 (m, 2H), 6.81 (d, $J = 8.7$ Hz, 2H), 4.58 (d, $J = 4.1$ Hz, 1H), 4.17-4.08 (m, 1H), 3.78 (s, 3H), 3.76 (s, 3H), 3.73 (s, 3H), 3.64-3.56 (m, 2H), 3.24 (q, $J = 9.8$ Hz, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ : 193.47, 161.49, 158.33, 141.46, 137.68, 136.05, 135.62, 129.65, 128.51, 128.04,


127.02, 126.61, 121.00, 118.95, 118.91, 113.81, 108.66, 108.14, 56.46, 55.21, 52.90, 38.32, 38.10, 29.32, 25.64. HRMS (ESI) m/z calcd. for $C_{29}H_{28}NO_4$ [M+H]⁺: 454.2013, found: 454.2015.

Methyl 2-((2*R*,3*R*,4*S*)-4-(2,5-dimethoxyphenyl)-9-methyl-2-phenyl-2,3,4,9-tetrahydro-1*H*-carbazol-3-yl)-2-oxoacetate (3o)




Yield: 84%, yellow solid. HPLC: Chiralpak AD-H (hexane/i-PrOH = 95/5, flow rate 0.5 mL/min, λ = 220 nm), t_{major} = 20.40 min, t_{minor} = 15.60 min, 91% ee. $[a]_D^{25}$ = +1.2 (c = 0.82, CH₂Cl₂). mp 197-203 °C. ¹H NMR (400 MHz, CDCl₃) δ : 7.32-7.23 (m, 2H), 7.23-7.10 (m, 5H), 7.06 (d, J = 7.8 Hz, 1H), 6.96-6.89 (m, 1H), 6.87 (d, J = 8.8 Hz, 1H), 6.73 (dd, J = 8.8, 3.1 Hz, 1H), 6.44 (d, J = 3.1 Hz, 1H), 4.89 (s, 1H), 4.17-4.05 (m, 1H), 3.86 (s, 3H), 3.72 (s, 3H), 3.62 (s, 3H), 3.59 (s, 3H), 3.53 (d, J = 11.1 Hz, 2H), 3.10 (q, J = 11.2 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ : 195.88, 162.75, 153.27, 151.09, 141.69, 137.77, 136.87, 133.02, 128.45, 127.81, 126.87, 126.62, 120.86, 118.81, 118.61, 117.63, 110.90, 110.77, 108.59, 106.70, 55.80, 55.55, 52.78, 52.43, 38.17, 33.81, 29.27, 24.80. HRMS (ESI) m/z calcd. for $C_{30}H_{30}NO_5$ [M+H]⁺: 484.2118, found: 484.2115.

Methyl 2-((2*R*,3*R*,4*S*)-4-(furan-2-yl)-9-methyl-2-phenyl-2,3,4,9-tetrahydro-1*H*-carbazol-3-yl)-2-oxoacetate (3p)




Yield: 86%, pale yellow solid. HPLC: Chiralpak AD-H (hexane/i-PrOH = 90/10, flow rate 0.6 mL/min, λ = 220 nm), t_{major} = 15.03 min, t_{minor} = 13.58 min, 42% ee. $[a]_D^{25}$ = -0.4 (c = 0.71, CH₂Cl₂). mp 140-146 °C. ¹H NMR (400 MHz, CDCl₃) δ : 7.39 (dd, J = 1.8, 0.8 Hz, 1H), 7.34-7.10 (m, 8H), 7.06-6.96 (m, 1H), 6.27 (dd, J = 3.1, 1.9 Hz, 1H), 6.07-5.96 (m, 1H), 4.69 (d, J = 4.0 Hz, 1H), 4.45-4.35 (m, 1H), 3.78-3.72 (m, 1H), 3.71 (s, 3H), 3.70 (s, 3H), 3.57-3.47 (m, 1H), 3.20 (dd, J = 16.3, 5.9 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ : 193.62, 161.46, 155.63, 141.84, 141.08, 137.47, 135.62, 128.58, 127.97, 127.18, 126.46, 121.11, 119.18, 118.46, 110.24, 108.79, 108.14, 106.27, 52.89, 52.35, 38.83, 33.48, 29.29, 25.29. HRMS (ESI) m/z calcd. for $C_{26}H_{24}NO_4$ [M+H]⁺: 414.1700, found: 414.1704.

Methyl 2-((2*R*,3*R*,4*R*)-2-(4-bromophenyl)-9-methyl-4-phenyl-2,3,4,9-tetrahydro-1*H*-carbazol-3-yl)-2-oxoacetate (3q)




Yield: 82%, pale yellow solid. HPLC: Chiralpak AD-H (hexane/*i*-PrOH = 95/5, flow rate 0.5 mL/min, λ = 220 nm), t_{major} = 18.48 min, t_{minor} = 34.28 min, 59% ee. $[a]_D^{25}$ = -56.7 (c = 0.82, CH₂Cl₂). mp 171-177 °C. ¹H NMR (400 MHz, CDCl₃) δ : 7.41-7.36 (m, 2H), 7.36-7.22 (m, 6H), 7.18 (ddd, J = 8.2, 4.6, 3.6 Hz, 1H), 7.01 (d, J = 8.5 Hz, 2H), 6.94 (d, J = 4.2 Hz, 2H), 4.65 (d, J = 4.2 Hz, 1H), 4.16 (dd, J = 4.2, 3.0 Hz, 1H), 3.81 (s, 3H), 3.76 (s, 3H), 3.67-3.57 (m, 2H), 3.26 (dd, J = 19.3, 9.4 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ : 193.11, 161.36, 143.32, 140.42, 137.70, 135.72, 131.59, 129.83, 128.62, 128.49, 126.79, 126.47, 121.16, 120.94, 119.06, 118.85, 108.72, 107.71, 56.15, 53.02, 39.03, 37.60, 29.36, 25.54. HRMS (ESI) *m/z* calcd. for C₂₈H₂₅BrNO₃ [M+H]⁺: 502.1012, found: 502.1015.

Methyl 2-((2*R*,3*R*,4*S*)-2-(4-bromophenyl)-4-(2-fluorophenyl)-9-methyl-2,3,4,9-tetrahydro-1*H*-carbazol-3-yl)-2-oxoacetate (3r)




Yield: 79%, pale yellow solid. HPLC: Chiralpak AD-H (hexane/*i*-PrOH = 95/5, flow rate 0.6 mL/min, λ = 220 nm), t_{major} = 20.00 min, t_{minor} = 24.34 min, 56% ee. $[a]_D^{25}$ = -28.8 (c = 0.82, CH₂Cl₂). mp 203-208 °C. ¹H NMR (400 MHz, CDCl₃) δ : 7.36 (d, J = 8.4 Hz, 2H), 7.31 (d, J = 8.2 Hz, 1H), 7.26-7.19 (m, 1H), 7.15 (ddd, J = 8.2, 5.7, 2.5 Hz, 1H), 7.13-7.06 (m, 1H), 7.02-6.89 (m, 6H), 4.86 (d, J = 4.0 Hz, 1H), 4.16 (t, J = 3.7 Hz, 1H), 3.73 (s, 3H), 3.72 (s, 3H), 3.61 (ddd, J = 9.0, 5.7, 3.4 Hz, 1H), 3.56-3.44 (m, 1H), 3.24 (dd, J = 16.2, 5.8 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ : 193.90, 161.75, 160.69 (¹J_{CF} = 247.4 Hz), 140.04, 137.69, 135.80, 131.64, 130.97, 130.93, 129.83 (d, ²J_{CF} = 13.3 Hz), 129.67, 128.72, 128.64, 126.14, 124.04, 124.01, 121.24, 121.04, 119.15, 118.43, 115.63 (d, ²J_{CF} = 20.47 Hz), 108.79, 106.79, 53.67, 52.88, 37.97, 32.96, 29.35, 25.40. HRMS (ESI) *m/z* calcd. for C₂₈H₂₄BrFNO₃ [M+H]⁺: 520.0918, found: 520.0920.

Methyl 2-((2*R*,3*R*,4*S*)-2-(4-bromophenyl)-4-(2,5-dimethoxyphenyl)-9-methyl-2,3,4,9-tetrahydro-1*H*-carbazol-3-yl)-2-oxoacetate (3s)




Yield: 82%, yellow solid. HPLC: Chiralpak AD-H (hexane/*i*-PrOH = 90/10, flow rate 0.6 mL/min, λ = 220 nm), t_{major} = 18.82 min, t_{minor} = 15.42 min, 68% ee. $[\alpha]_D^{25} = +11.0$ ($c = 0.92$, CH_2Cl_2). mp 185-187 °C. ^1H NMR (400 MHz, CDCl_3) δ : 7.41-7.33 (m, 2H), 7.29 (d, $J = 8.2$ Hz, 1H), 7.18-7.10 (m, 1H), 7.05 (d, $J = 8.4$ Hz, 3H), 6.97-6.90 (m, 1H), 6.87 (d, $J = 8.8$ Hz, 1H), 6.73 (dd, $J = 8.8, 3.1$ Hz, 1H), 6.41 (d, $J = 3.1$ Hz, 1H), 4.88 (s, 1H), 4.06 (dd, $J = 3.1, 2.2$ Hz, 1H), 3.86 (s, 3H), 3.72 (s, 3H), 3.68 (s, 3H), 3.59 (s, 3H), 3.56-3.38 (m, 2H), 3.08 (dd, $J = 15.3, 4.9$ Hz, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ : 195.53, 162.77, 153.27, 151.04, 140.82, 137.76, 136.49, 132.73, 131.51, 129.66, 126.51, 121.00, 120.72, 118.90, 118.58, 117.64, 110.95, 110.81, 108.64, 106.59, 55.80, 55.53, 52.66, 52.56, 37.64, 33.75, 29.29, 24.83. HRMS (ESI) m/z calcd. for $\text{C}_{30}\text{H}_{29}\text{BrNO}_5$ [$\text{M}+\text{H}]^+$: 562.1224, found: 562.1225.

Methyl 2-((2*R*,3*R*,4*S*)-2-(4-bromophenyl)-4-(2-methoxyphenyl)-9-methyl-2,3,4,9-tetrahydro-1*H*-carbazol-3-yl)-2-oxoacetate (3t)



Yield: 69%, pale yellow solid. HPLC: Chiralpak AD-H (hexane/*i*-PrOH = 95/5, flow rate 0.6 mL/min, λ = 220 nm), t_{major} = 16.46 min, t_{minor} = 30.33 min, 90% ee. $[\alpha]_D^{25} = -5.2$ ($c = 0.73$, CH_2Cl_2). mp 171-178 °C. ^1H NMR (400 MHz, CDCl_3) δ : 7.39 (d, $J = 8.5$ Hz, 2H), 7.33 (d, $J = 8.2$ Hz, 1H), 7.24 (dd, $J = 7.7, 1.4$ Hz, 1H), 7.21-7.14 (m, 1H), 7.07 (dd, $J = 7.6, 5.5$ Hz, 3H), 7.00-6.91 (m, 2H), 6.82 (dd, $J = 7.5, 1.7$ Hz, 1H), 6.76 (td, $J = 7.4, 0.8$ Hz, 1H), 4.94 (s, 1H), 4.08 (dt, $J = 22.1, 11.1$ Hz, 1H), 3.93 (s, 3H), 3.76 (s, 3H), 3.71 (s, 3H), 3.62-3.51 (m, 1H), 3.49-3.38 (m, 1H), 3.12 (dd, $J = 15.8, 5.4$ Hz, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ : 195.67, 162.79, 156.62, 140.88, 137.72, 136.61, 131.51, 131.07, 129.90, 129.66, 128.03, 126.54, 121.03, 120.72, 120.28, 118.90, 118.65, 110.32, 108.65, 106.79, 55.30, 52.70, 52.57, 37.75, 33.65, 29.32, 24.83. HRMS (ESI) m/z calcd. for $\text{C}_{29}\text{H}_{27}\text{BrNO}_4$ [$\text{M}+\text{H}]^+$: 532.1118, found: 532.1118.


Methyl 2-((2*R*,3*R*,4*R*)-9-methyl-4-phenyl-2-(*p*-tolyl)-2,3,4,9-tetrahydro-1*H*-carbazol-3-yl)-2-oxoacetate (3u)



Yield: 73%, pale yellow solid. HPLC: Chiralpak AD-H (hexane/*i*-PrOH = 95/5, flow rate 0.5 mL/min, λ = 220 nm), t_{major} = 18.82 min, t_{minor} = 28.65 min, 56% ee. $[\alpha]_D^{25} = -59.1$ ($c = 0.64$, CH_2Cl_2). mp 176-180 °C. ^1H NMR (400 MHz, CDCl_3) δ : 7.33-7.18 (m, 6H), 7.14 (dt, $J = 8.2, 4.1$ Hz, 1H), 7.00-6.91 (m, 2H), 6.82 (dd, $J = 7.5, 1.7$ Hz, 1H), 6.76 (td, $J = 7.4, 0.8$ Hz, 1H), 4.94 (s, 1H), 4.08 (dt, $J = 22.1, 11.1$ Hz, 1H), 3.93 (s, 3H), 3.76 (s, 3H), 3.71 (s, 3H), 3.62-3.51 (m, 1H), 3.49-3.38 (m, 1H), 3.12 (dd, $J = 15.8, 5.4$ Hz, 1H).

Hz, 1H), 7.03 (d, J = 8.1 Hz, 2H), 6.98 (d, J = 8.2 Hz, 2H), 6.90 (d, J = 3.9 Hz, 2H), 4.61 (d, J = 4.4 Hz, 1H), 4.15 (dd, J = 4.4, 3.1 Hz, 1H), 3.76 (s, 3H), 3.72 (s, 3H), 3.66-3.51 (m, 2H), 3.24 (dd, J = 15.2, 4.9 Hz, 1H), 2.28 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ : 193.39, 161.46, 143.59, 138.31, 137.66, 136.63, 136.18, 129.19, 128.72, 128.40, 127.88, 126.63, 126.59, 120.96, 118.93, 118.86, 108.64, 107.92, 56.29, 52.89, 39.03, 37.81, 29.31, 25.87, 20.98. HRMS (ESI) m/z calcd. for $\text{C}_{29}\text{H}_{28}\text{NO}_3$ [M+H] $^+$: 438.2064, found: 438.2063.

Methyl 2-((2*R*,3*R*,4*S*)-4-(2-methoxyphenyl)-9-methyl-2-(*p*-tolyl)-2,3,4,9-tetrahydro-1*H*-carbazol-3-yl)-2-oxoacetate (3v)




Yield: 91%, pale yellow solid. HPLC: Chiraldak AD-H (hexane/*i*-PrOH = 95/5, flow rate 0.6 mL/min, λ = 220 nm), t_{major} = 15.60 min, t_{minor} = 25.67 min, 50% ee. $[a]_D^{25} = -2.2$ (c = 0.85, CH_2Cl_2). mp 174-178 °C. ^1H NMR (400 MHz, CDCl_3) δ : 7.30 (d, J = 8.2 Hz, 1H), 7.22-7.18 (m, 1H), 7.13 (t, J = 7.6 Hz, 1H), 7.09-7.00 (m, 5H), 6.97-6.88 (m, 2H), 6.82 (dd, J = 7.5, 1.6 Hz, 1H), 6.74 (t, J = 7.3 Hz, 1H), 4.91 (s, 1H), 4.10 (dt, J = 15.0, 7.5 Hz, 1H), 3.89 (s, 3H), 3.72 (s, 3H), 3.63 (s, 3H), 3.58-3.36 (m, 2H), 3.09 (dd, J = 15.3, 4.6 Hz, 1H), 2.28 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ : 196.11, 162.78, 156.68, 138.70, 137.70, 137.09, 136.42, 131.40, 129.94, 129.11, 127.86, 127.68, 126.67, 120.85, 120.23, 118.78, 118.68, 110.26, 108.59, 106.92, 55.28, 52.88, 52.42, 37.94, 33.69, 29.28, 24.98, 20.97. HRMS (ESI) m/z calcd. for $\text{C}_{30}\text{H}_{30}\text{NO}_4$ [M+H] $^+$: 468.2169, found: 468.2167.

7. References


- 1 a) N. Lin, M.-M. Chen, R.-S. Luo, Y.-Q. Deng, G. Lu, *Tetrahedron: Asymmetry* 2010, **21**, 2816; b) R.-S. Luo, J. Weng, H.-B. Ai, G. Lu, A. S. C. Chan, *Adv. Synth. Catal.* 2009, **351**, 2449; c) F. Andersson, E. Hedenström, *Tetrahedron: Asymmetry* 2006, **17**, 1952; d) K. M. B. Gross, Y. M. Jun, P. Beak, *J. Org. Chem.* 1997, **62**, 7679; e) J. Martens, C. Dauelsberg, W. Behnen, S. Wallbaum, *Tetrahedron: Asymmetry* 1992, **3**, 347.
- 2 a) B. Liégault, X. Tang, C. Bruneau, J.-L. Renaud, *Eur. J. Org. Chem.* 2008, 934; b) G. Kokotos, E. Bellis, K. Vasilatou, *Synthesis* 2005, **14**, 2407.
- 3 J. V. B. Kantb, M. Perlasamy, *Tetrahedron* 1993, **49**, 5127.
- 4 a) D. A. Evans, G. S. Peterson, J. S. Johnson, D. M. Barnes, K. R. Campos, K. A. Woerpel, *J. Org. Chem.* 1998, **63**, 4541; b) D. A. Evans, K. A. Woerpel, B. Nosse, A. Schall, Y. Shinde, E. Jezek, M. M. Haque, R. B. Chhor, O. Reiser, *Organic Syntheses* 2006, **83**, 97.
- 5 a) L. Gremaud, A. Alexakis, *Angew. Chem., Int. Ed.* 2012, **51**, 794; b) D. Belmessieri, L. C. Morrill,

- C. Simal, A. M. Slawin, A. D. Smith, *J. Am. Chem. Soc.* 2011, **133**, 2714.
- 6 R. V. Hoffman, M. C. Johnson, J. F. Okonya, *J. Org. Chem.* 1997, **62**, 2458.
- 7 C. S. Vu, N. Guisot, S. Guillarme, A. Martel, G. Dujardin, M. Pipelier, D. Dubreuil, C. Saluzzo, *Eur. J. Org. Chem.* 2012, 3727.
- 8 C. Zheng, Y. Lu, J. Zhang, X. Chen, Z. Chai, W. Ma, G. Zhao, *Chem. Eur. J.* 2010, **16**, 5853.


8. HPLC spectra




Racemic product




Optically enriched product







Racemic product




Optically enriched product







Racemic product




Optically enriched product







Racemic product




Optically enriched product







Racemic product




Optically enriched product







Racemic product




Optically enriched product







Racemic product






Optically enriched product






Racemic product







Racemic product




Optically enriched product






Racemic product




峰 #	保留时间 [min]	类型	峰宽 [min]	峰面积 [mAU*s]	峰高 [mAU]	峰面积 %
1	18.568	BB	0.3744	483.74014	19.56830	2.0816
2	20.576	BB	0.4248	1.11293e4	397.34753	47.8908
3	24.753	BB	0.4952	494.84872	15.06671	2.1294
4	29.206	BB	0.6102	1.11310e4	280.95950	47.8982


Optically enriched product




峰 #	保留时间 [min]	类型	峰宽 [min]	峰面积 [mAU*s]	峰高 [mAU]	峰面积 %
1	18.696	BB	0.3808	2163.39648	85.61875	5.0472
2	21.136	BB	0.4564	3.21746e4	1077.556104	75.0631
3	24.925	BB	0.4945	328.68707	9.92151	0.7668
4	30.936	BB	0.6584	8196.71484	191.87932	19.1229




Racemic product




Optically enriched product







Racemic product




Optically enriched product







Racemic product




Optically enriched product







Racemic product




Optically enriched product







Racemic product




Optically enriched product







Racemic product




Optically enriched product







Racemic product




Optically enriched product







Racemic product




Optically enriched product







Racemic product




Optically enriched product







3t

Racemic product




Optically enriched product







3u

Racemic product




Optically enriched product






Racemic product



Optically enriched product



9. ^1H and ^{13}C NMR spectra

